These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37647693)

  • 1. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.
    Liu C; Chen H; Guo S; Liu Q; Chen Z; Huang H; Zhao Q; Li L; Cen H; Jiang Z; Luo Q; Chen X; Zhao J; Chen W; Yang PC; Wang L
    Biomed Pharmacother; 2023 Oct; 166():115373. PubMed ID: 37647693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
    Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
    Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
    Kimmick G; Dent S; Klem I
    Curr Treat Options Cardiovasc Med; 2019 May; 21(6):30. PubMed ID: 31152324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
    Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
    Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
    Smith TA; Phyu SM; Akabuogu EU
    Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
    Varghese SS; Eekhoudt CR; Jassal DS
    Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Chemotherapy Induced Cardiomyopathy.
    Payne DL; Nohria A
    Curr Heart Fail Rep; 2017 Oct; 14(5):398-403. PubMed ID: 28779279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
    Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
    Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report.
    Kuruc JC; Durant-Archibold AA; Motta J; Rao KS; Trachtenberg B; Ramos C; Wang H; Gorenstein D; Vannberg F; Jordan K
    BMC Cardiovasc Disord; 2019 Jul; 19(1):169. PubMed ID: 31311496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac safety of liposomal anthracyclines.
    Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.